Analysts expect that the resubmission of Eli Lilly & Co./Incyte Corp.'s JAK1/2 inhibitor baricitinib in rheumatoid arthritis will be successful and that the drug will be received warmly in the market by specialists, despite concerns by the US FDA about thromboembolic safety.
Lilly and Incyte announced Aug. 30 that they will be resubmitting the NDA for the once-daily JAK inhibitor in moderate-to-severe...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
